Pages that link to "Q35127833"
Jump to navigation
Jump to search
The following pages link to Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis (Q35127833):
Displaying 35 items.
- Gain of function mutations in CgPDR1 of Candida glabrata not only mediate antifungal resistance but also enhance virulence (Q27318203) (← links)
- Anidulafungin and voriconazole in invasive fungal disease: pharmacological data and their use in combination (Q33490772) (← links)
- In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species (Q33876423) (← links)
- Pharmacokinetics and tissue distribution of anidulafungin in rats (Q34591184) (← links)
- Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model (Q35105763) (← links)
- Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts (Q35270758) (← links)
- Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia (Q35647785) (← links)
- Antifungal pharmacokinetics and pharmacodynamics (Q35663841) (← links)
- Comparative effects of micafungin, caspofungin, and anidulafungin against a difficult-to-treat fungal opportunistic pathogen, Candida glabrata (Q35806170) (← links)
- Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature (Q35959484) (← links)
- In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. (Q36425025) (← links)
- Mechanism-based pharmacokinetic-pharmacodynamic models of in vitro fungistatic and fungicidal effects against Candida albicans (Q36482785) (← links)
- Pharmacodynamics of anidulafungin against clinical Aspergillus fumigatus isolates in a nonneutropenic murine model of disseminated aspergillosis. (Q36505281) (← links)
- Anidulafungin--state of affairs from a clinical perspective. (Q36774257) (← links)
- Anidulafungin in the treatment of invasive fungal infections (Q36822941) (← links)
- Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. (Q36845482) (← links)
- Anidulafungin treatment of candidal central nervous system infection in a murine model (Q37274734) (← links)
- Evaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility (Q37291442) (← links)
- Anidulafungin: a novel echinocandin for candida infections (Q37345790) (← links)
- Paradoxical echinocandin activity: a limited in vitro phenomenon? (Q37405284) (← links)
- Echinocandin pharmacodynamics: review and clinical implications. (Q37718385) (← links)
- Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis (Q37720794) (← links)
- Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections (Q37785979) (← links)
- Is Fluconazole or an Echinocandin the Agent of Choice for Candidemia. (Q38535647) (← links)
- Anidulafungin and its role in candida infections (Q42731827) (← links)
- In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera (Q42845954) (← links)
- Activity of anidulafungin in a murine model of Candida krusei infection: evaluation of mortality and disease burden by quantitative tissue cultures and measurement of serum (1,3)-beta-D-glucan levels (Q43153532) (← links)
- Anidulafungin: experimental therapy of fungal infections in animal models (Q44563761) (← links)
- [Potential of anidulafungin in hematological patients]. (Q45942584) (← links)
- [Pharmacokinetics and pharmacodynamics: interactions and adverse effects. Comparison with other echinocandins]. (Q45942595) (← links)
- Pharmacodynamics of the Long Acting Echinocandin, CD101, in the Neutropenic Invasive Candidiasis Murine Model Using an Extended Interval Dosing Design (Q46248423) (← links)
- A quantitative systems pharmacology (QSP) model for Pneumocystis treatment in mice (Q57175587) (← links)
- In silico-derived bedside formula for individualized micafungin dosing for obese patients in the age of deterministic chaos (Q58033439) (← links)
- Evaluation of anidulafungin in the treatment of intra-abdominal candidiasis: a pooled analysis of patient-level data from 5 prospective studies (Q91681606) (← links)
- Pros and Cons of Extrapolating Animal Data on Antifungal Pharmacodynamics to Humans (Q91876531) (← links)